Navigation Links
Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
Date:3/24/2011

THE WOODLANDS, Texas, March 24, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Pablo Lapuerta, M.D. has joined the company as its chief medical officer, responsible for directing clinical development of Lexicon's drug candidates from Phase 2 proof-of-concept through Phase 3 and approval.  Dr. Lapuerta has 15 years of pharmaceutical industry experience in a variety of leadership roles in drug development, global medical affairs and outcomes research strategy across multiple therapeutic areas, including cardiovascular disease, endocrinology, gastroenterology, and neurology.  Most recently, Dr. Lapuerta served as vice president at Bristol-Myers Squibb where he was responsible for global development of an Alzheimer's disease drug candidate with the associated use of an innovative biomarker.

(Photo:  http://photos.prnewswire.com/prnh/20110324/DA71095)

"Dr. Lapuerta's extensive experience in clinical development, regulatory strategy, and medical affairs are especially valuable as we progress the four programs we currently have in mid-stage clinical studies," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon.  "His breadth of knowledge in multiple therapeutic areas meshes well with Lexicon's broad pipeline in drug discovery and development."

Dr. Lapuerta obtained his undergraduate degree from Harvard College and his medical degree from Harvard Medical School. He completed his training in internal medicine at the University of North Carolina at Chapel Hill followed by a post-doctoral research fellowship at the University of California at Los Angeles in neuroscience. He served as assistant p
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... July 21, 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, announced today that it will host a ... to discuss results for the period ended June 30, ... with respect to its clinical program for aramchol. ...
(Date:7/21/2014)... Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... treatments for cancer and its associated pain, today announced ... development of a small molecule inhibitor targeting the important ... protein has also been recognized as an important determinant ... as a dominant factor in most human cancers and ...
(Date:7/21/2014)... MARYVILLE, Ill. , July 21, 2014 /PRNewswire-iReach/ ... that Dr. Ryan Diederich has been ... on Membership and Advocacy for 2014-2015. This council ... member resources, services and benefits. The ... that represents and unifies its physician members as ...
Breaking Medicine Technology:Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014 2Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 2Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 3Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 4
... Dec. 21, 2011  VIVUS, Inc. (NASDAQ: VVUS ... retrospective study of medical claims data on oral ... utero .  The study, known as FORTRESS for ... mother-infant dyads exposed to topiramate either alone (monotherapy) ...
... Dec. 21, 2011 Despite the numerous medical advances ... the United States is still higher than most European ... the growing rate of pre-term births, researchers are committed ... Northwestern Medicine ® researchers are examining ...
Cached Medicine Technology:VIVUS Reports Topline Findings From FORTRESS 2VIVUS Reports Topline Findings From FORTRESS 3VIVUS Reports Topline Findings From FORTRESS 4VIVUS Reports Topline Findings From FORTRESS 5VIVUS Reports Topline Findings From FORTRESS 6Northwestern Researchers Trial New Device that May Support Improved Newborn Health 2Northwestern Researchers Trial New Device that May Support Improved Newborn Health 3Northwestern Researchers Trial New Device that May Support Improved Newborn Health 4
(Date:7/22/2014)... With over 170,000 students now playing high school ... during practice and competition, according to a new study ... Center for Injury Research and Policy at Nationwide Children,s ... today by The American Journal of Sports Medicine ... injuries over the four academic years from 2008 through ...
(Date:7/22/2014)... 22, 2014 CareTouch Communications, Inc. has ... in the Community . CareTouch employees will select causes ... hands-on support in line with their mission to help ... The program’s first cause is Hike for Hospice, to ... On Sunday, September 14, the CareTouch in the Community ...
(Date:7/22/2014)... 22, 2014 A new and technologically ... laxity with results that are surprising even the most ... the skin with radio frequency, ThermiTight has been dubbed ... under the skin to “inject” heat to the tissues ... this single treatment solution for skin laxity produces results ...
(Date:7/21/2014)... one of the fastest-growing high school sports in the ... the sometimes hard-hitting game. The growing participation numbers, however, ... risk of injury in lacrosse practice and competition. , ... American Journal of Sports Medicine and available in ... Injury Research and Policy at Nationwide Children,s Hospital and ...
(Date:7/21/2014)... iFitDress.com, a famous company of wedding ... its exclusive collection of 2014 glitter evening dresses ... its brand new gowns. , iFitDress.com is one of ... Its sales boomed in the recent years, not just ... because of the amicable services offered on its website. ...
Breaking Medicine News(10 mins):Health News:High school lacrosse players at risk of concussions other injuries 2Health News:High school lacrosse players at risk of concussions other injuries 3Health News:CareTouch is a Peak Sponsor for the 9th Annual Hike for Hospice in Morrison, Colorado 2Health News:New Minimally Invasive Procedure, ThermiTight, “Injects” Radio Frequency to Treat Skin Laxity 2Health News:New study finds high school lacrosse players at risk for concussions, other injuries 2Health News:New study finds high school lacrosse players at risk for concussions, other injuries 3Health News:iFitDress.com: 2014 Glitter Evening Dresses For Worldwide Clients 2
... Change to Win Executive Director Greg Tarpinian on the ... to prevent employee,misclassification by New York Governor Eliot Spitzer:, ... unions with six million members,in the growth occupations and ... care, from construction and transportation to food,processing and hospitality ...
... program where small changes make a huge impact, ... as we celebrate the end of Healthy Steps, a ... Philadelphia Housing,Authority, and Philadelphia Safe and Sound on Friday, ... Community Center, 2500 Jackson Street in,South Philadelphia., The ...
... Kaiser Permanente has successfully,certified its greenhouse gas ... becoming the first health care organization to,earn the ... now,publicly and voluntarily reporting its 2006 GHG emissions ... paying attention to the organization,s impact on,the environment ...
... from the Centers for Disease Control and Prevention over ... in eight countries that lack the large-scale public health ... of the grant will support the efforts of Tulane ... of Ethiopia and rural Jimma University, to train ...
... Sept. 7 As states consider,proposals to expand ... assesses,the impact of prior efforts in states across ... launched "insurance reforms" with significant,unintended consequences. A number ... a few years of implementation. The study by,Milliman, ...
... N.C., Sept. 7 Pharmaceutical companies,face a unique ... and marketing forces, and quality production processes while ... The case studies in the,Multi-Year Compendium of Pharmaceutical ... were presented by industry leaders at Global,Benchmarking Council ...
Cached Medicine News:Health News:Tarpinian: Misclassification is Theft 2Health News:Tarpinian: Misclassification is Theft 3Health News:On September 7th Local Organizations Partner to Celebrate 'Healthy Steps' 2Health News:Kaiser Permanente Achieves Climate Action Leader Status 2Health News:Tulane University to receive $14M for international HIV/AIDS program 2Health News:New AHIP Report Takes a Ten Year Look at the Unintended Consequences of State Efforts to Change the Insurance Market 2Health News:Multi-Year Compendium of Pharmaceutical Case Studies Available from Best Practices, LLC 2
Each handle is designed to fit a specific trephine size....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: